MRI to Predict Outcomes of PDAC
Condition: Pancreatic ductal adenocarcinoma
Key Inclusion Criteria:
- Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy
- Able to undergo at least two sets of magnetic resonance imaging (MRI) sessions
- Access to a device that has the capability to sync to the Fitbit (or access to a family member, caregiver, or friend’s device)
Key Exclusion Criteria:
- Previously treated for pancreatic ductal adenocarcinoma
- Unable to undergo MRI exam with contrast
- Patients with metastatic pancreatic cancer visualized on index diagnostic imaging
Full Study Name
MRI Imaging to Predict Outcomes of Treatment in PDAC Patients (IRB no. 00000573)
This study focuses on patients who are receiving care for non-metastatic pancreatic cancer at Cedars-Sinai. The purpose of the study is to evaluate the role of a method of magnetic resonance imaging (MRI) analysis for individuals with pancreatic ductal adenocarcinoma (PDAC). Researchers aim to determine whether their newly developed, six-dimensional magnetic resonance imaging (6D-MRI) is effective in predicting outcomes to therapy in PDAC patients. 6D-MRI is a type of image analysis that can visualize high-resolution images of the pancreas and pancreatic tumors taken during MRI scans. These non-standard imaging techniques are for research purposes only.
Participants will be asked to undergo 3 separate 6D-MRI procedures during the course of their cancer treatment. 6D-MRI provides a more complex analysis of images generated during the MRI than images from a standard MRI; there are no procedural differences between 6D-MRI and standard MRI. Participants should not expect to benefit from taking part in this study. Researchers hope to learn whether specific findings in the 6D-MRI can help select the best therapy for other patients in the future with the result of improving outcome.